Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021

JAMA Intern Med. 2023 Mar 1;183(3):275-276. doi: 10.1001/jamainternmed.2022.6299.
No abstract available

Plain language summary

This cross-sectional study assesses Medicaid spending associated with citrate-free vs original adalimumab.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Citrates
  • Citric Acid*
  • Health Expenditures
  • Humans
  • Medicaid*
  • United States

Substances

  • Adalimumab
  • Citric Acid
  • Citrates